Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Citrin

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Cancer|August 1, 1983
Chemohormonal therapy of metastatic prostate cancer. A pilot studyD L Citrin, T F Hogan, T E Davis
JAMA|July 11, 1980
Hyperaldosteronism associated with liver metastasesK J Pandya, R Whitehead, J Crowley, et al.
The American Journal of Medicine|May 1, 1984
Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implicationsD L Citrin, P Elson, M S Kies, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1975
Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumorsD L Citrin, R G Bessent, E McGinley, et al.
Cancer|June 1, 1980
A clinical and pathological study of adrenocortical carcinoma: therapeutic implicationsT F Hogan, K W Gilchrist, D W Westring, et al.
European Journal of Nuclear Medicine|January 1, 1978
A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.PI Fogelman, C Goll, J H McKillop, et al.
The Journal of Urology|February 1, 1981
Systemic treatment of advanced prostatic cancer: development of a new system for defining responseD L Citrin, A I Cohen, J Harberg, et al.
The Oncologist|April 26, 2012
Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapiesDennis L Citrin, Diane L Bloom, James F Grutsch, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancerN B Haas, J Manola, G Hudes, et al.
Cancer|November 1, 1978
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacementT F Hogan, D L Citrin, B M Johnson, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Cancer|August 1, 1983
Chemohormonal therapy of metastatic prostate cancer. A pilot studyD L Citrin, T F Hogan, T E Davis
JAMA|July 11, 1980
Hyperaldosteronism associated with liver metastasesK J Pandya, R Whitehead, J Crowley, et al.
The American Journal of Medicine|May 1, 1984
Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implicationsD L Citrin, P Elson, M S Kies, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1975
Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumorsD L Citrin, R G Bessent, E McGinley, et al.
Cancer|June 1, 1980
A clinical and pathological study of adrenocortical carcinoma: therapeutic implicationsT F Hogan, K W Gilchrist, D W Westring, et al.
European Journal of Nuclear Medicine|January 1, 1978
A clinical comparison of 2 h and 4 h bone scans obtained with 99Tc H.E.D.PI Fogelman, C Goll, J H McKillop, et al.
The Journal of Urology|February 1, 1981
Systemic treatment of advanced prostatic cancer: development of a new system for defining responseD L Citrin, A I Cohen, J Harberg, et al.
The Oncologist|April 26, 2012
Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapiesDennis L Citrin, Diane L Bloom, James F Grutsch, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancerN B Haas, J Manola, G Hudes, et al.
Cancer|November 1, 1978
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacementT F Hogan, D L Citrin, B M Johnson, et al.
Pageof 4